MAIA Biotechnology’s Lung Most cancers Drug Exhibits Promising Lengthy-Time period Advantages In Superior Sufferers – MAIA Biotechnology (AMEX:MAIA)

On Tuesday, MAIA Biotechnology Inc MAIA introduced therapy updates from its Part 2 THIO-101 trial of THIO sequenced with Regeneron Prescribed drugs Inc’s REGN cemiplimab (Libtayo) for superior non-small-cell-lung-cancer sufferers who failed two or extra standard-of-care remedy regimens.

The trial’s therapeutic routine is cycled each three weeks, with THIO 180mg administered in 60mg incremental doses on days 1, 2 and three, adopted by immune activation on day 4 (no dosing), and cemiplimab 350mg administered on day 5.

As of the most recent medical cutoff date, June 12, 2024:

• Six sufferers stay on therapy following at the least 12 months of remedy.
• Therapy with THIO adopted by cemiplimab has been effectively tolerated all through the trial, with a lot decrease toxicity than standard-of-care remedies.
• Persevering with therapy previous 12 months demonstrates security, efficacy and ongoing profit from MAIA’s novel telomere focusing on NSCLC remedy.

“Our longest handled affected person thus far has accomplished 21 cycles of THIO sequenced with a CPI, and 6 sufferers who’ve crossed the 12-month survival follow-up are persevering with the therapy,” mentioned Vlad Vitoc, chairman and chief government officer of MAIA.

In June, MAIA Biotechnology shared new efficacy knowledge from its Part 2 THIO-101 examine of THIO.

Up to date outcomes present a positive total response charge (ORR) of 38% and a illness management charge (DCR) of 85% from THIO + CPI in third-line therapy:

• The illness management charge (DCR) was 85% for THIO vs. normal of care DCR of 25–35% for chemotherapy.
• 65% of sufferers crossed the 5.8-month total survival (OS) threshold.
• 85% of sufferers crossed the two.5-month progression-free survival (PFS) threshold.
• Median survival follow-up time is at present 9.1 months (n=20)

Value Motion: MAIA inventory is down 14.25% at $3.31 eventually verify Tuesday.

Learn Subsequent:

Picture created utilizing synthetic intelligence through Midjourney.